reports
- Sean Conroy
ADL Bionatur Solutions - CMO business driving growth
ADL Bionatur Solutions’ (ADL-BS) 9M19 results show €2.16m adjusted EBITDA and 127% year-on-year operating revenue growth to €33.2m, driven by 195% growth in contract manufacturing (CMO). On 2 December it announced a new seven-year CMO contract with a Swiss biotech client worth €20m to produce two novel cosmetics and/or nutrition products. ADL-BS is on track to report positive full-year EBITDA and maintained its FY19 revenue guidance of €50m. We now obtain an EV of €165.8m, translatin...
- Pooya Hemami
ADL Bionatur Solutions - €25m debt financing to fund current strateg...
ADL Bionatur Solutions (ADL-BS) announced on 12 August 2019 that it has agreed to obtain €25m in debt financing with Kartesia, a private lender, at a rate of Euriobor plus 5% per year with a one-time 7% fee on repayment. Gross proceeds will be used to fully fund the company’s existing capex plans to modernise ADL-BS’s contract manufacturing (CMO) facilities (totalling 2,400m3 in fermentation capacity), to provide the working capital needed to respond to its CMO client demands, and to refin...
- Pooya Hemami
ADL Bionatur Solutions - New contract to serve Asia-Pacific API market
ADL Bionatur Solutions (ADL-BS) announced on 7 August 2019 that it entered into a strategic alliance with an undisclosed new customer in Japan to produce sterile active pharmaceutical ingredients (APIs). The customer is a producer of pharmaceuticals, agricultural chemicals and veterinary drugs, and the revenues associated with the contract represent €13m over the next five years.
- Pooya Hemami
ADL Bionatur Solutions - Amyris contract extended to 2020
ADL Bionatur Solutions (ADL-BS) announced on 22 July 2019 that its existing contract manufacturing (CMO) production agreement with Amyris (AMRS, Nasdaq) has been extended to 2020, with the associated additional revenue expected to exceed €12m. Amyris develops and markets fermentation-derived ingredients for the health and clean beauty markets, and indicates that its current portfolio is growing over 100% in 2019. The contract expansion signals Amyris’s confidence in ADL-BS’s fermentation f...
- Pooya Hemami
ADL Bionatur Solutions - Q1 off to a good start, raising margin expect...
ADL Bionatur Solutions (ADL-BS) recently reported Q119 results, showing positive €0.11m EBITDA, and over 134% year-on-year revenue growth to €10m, driven by 180% growth in contract manufacturing (CMO). After increasing our margin assumptions and rolling forward our estimates, we now obtain an NPV of €163.1m, translating into an equity valuation of €3.02 per share (from €2.37 previously) after adjusting for net debt.
- Pooya Hemami
ADL Bionatur Solutions - Solid Q119 growth
ADL Bionatur Solutions (ADL-BS) reported robust Q119 growth, with revenue of €9.97m (up 134% year-on-year), driven largely by increased capacity utilisation at its contract manufacturing (CMO) business. CMO revenues were €8.02m (up 180% vs Q118), whereas the active pharmaceutical ingredient (API) segment was down 14% yearly to €0.90m, due in part to seasonality for β-lactam antibiotics. Other revenue, which includes proprietary products and other contracted services and income, was up 205...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.